vs
Side-by-side financial comparison of NEUROCRINE BIOSCIENCES INC (NBIX) and QIAGEN N.V. (QGEN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $805.5M | — | ||
| Q3 25 | $794.9M | — | ||
| Q2 25 | $687.5M | — | ||
| Q1 25 | $572.6M | — | ||
| Q4 24 | $627.7M | — | ||
| Q3 24 | $622.1M | — | ||
| Q2 24 | $590.2M | — | ||
| Q1 24 | $515.3M | — |
| Q4 25 | $153.7M | — | ||
| Q3 25 | $209.5M | — | ||
| Q2 25 | $107.5M | — | ||
| Q1 25 | $7.9M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $129.8M | — | ||
| Q2 24 | $65.0M | — | ||
| Q1 24 | $43.4M | — |
| Q4 25 | 97.8% | — | ||
| Q3 25 | 98.2% | — | ||
| Q2 25 | 98.4% | — | ||
| Q1 25 | 98.4% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 98.7% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.5% | — |
| Q4 25 | 26.2% | — | ||
| Q3 25 | 30.1% | — | ||
| Q2 25 | 21.2% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 29.5% | — | ||
| Q2 24 | 24.6% | — | ||
| Q1 24 | 19.3% | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 20.9% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 8.4% | — |
| Q4 25 | $1.49 | — | ||
| Q3 25 | $2.04 | — | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.08 | — | ||
| Q4 24 | $1.00 | — | ||
| Q3 24 | $1.24 | — | ||
| Q2 24 | $0.63 | — | ||
| Q1 24 | $0.42 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
